LDN Sweet Spot

Disclosure

Disclosure Statement
Yoon Hang Kim, MD owns Yoon Hang Kim MD, an integrative and functional medicine practice focused on LDN therapy. He has published an article and several books on LDN available on Amazon. He is an administrator for the FB LDN Support Group, LDN Support Group, and the Skool LDN Support Group.

Learning objectives

By the end of this presentation, participants should be able to:

1. Describe the proposed endorphin deficiency phenotype and its relationship to chronic pain, fatigue, poor sleep, and reduced stress tolerance.
2. Explain the proposed mechanism of LDN as brief opioid receptor blockade followed by compensatory upregulation of endogenous opioid function.
3. Distinguish between true intolerance and dose-related early worsening when patients begin LDN.
4. Identify patient groups who may require ultra-low-dose or slower titration, including medication-sensitive, fibromyalgia, ME/CFS, long COVID, and central-sensitization phenotypes.
5. Apply a practical method to find a patient’s LDN sweet spot using symptoms, sleep, mood, and tolerability as clinical guideposts.

Case studies

Case study 1

Title: Fibromyalgia / ME-CFS phenotype with dose overshoot

Clinical scenario

• A 45-year-old woman with long-standing fibromyalgia presents with chronic widespread pain, non-restorative sleep, fatigue, brain fog, and marked medication sensitivity.
• She starts LDN at a standard low dose and within several days develops vivid dreams, more fragmented sleep, irritability, and a short-term pain flare.

Teaching points

• This pattern fits dose overshoot in a sensitive patient, not evidence that LDN is causing chronic endorphin deficiency.
• The sweet-spot framework suggests lowering the dose substantially, slowing titration, and reassessing after stabilization.
• This case highlights why patients with fibromyalgia- or ME/CFS-like symptom clusters may need far lower initial doses than standard protocols assume.

Clinical takeaway

• “Worse at first” may mean too much, too fast, rather than “LDN is not for this patient.”

Case study 2

Title: Long COVID / neuroimmune phenotype with gradual benefit

Clinical scenario

• A patient with long COVID presents with fatigue, pain, exertional intolerance, brain fog, poor recovery, and sleep dysregulation.
• LDN is introduced with cautious titration because of high sensitivity and fluctuating symptom burden.

Teaching points

• The rationale includes both endogenous opioid rebound effects and neuroimmune modulation, including discussion of microglial and TRPM3-related mechanisms in your article set.
• Improvement is tracked across fatigue, cognition, sleep quality, pain, and functional recovery rather than pain alone.
• This case reinforces that the ideal dose is the lowest dose that improves regulation without sustained activation, dysphoria, or worsening sleep.

Clinical takeaway

• In post-viral or neuroinflammatory patients, success often depends on precision titration and patience, not aggressive escalation.

Multiple-choice questions

Question 1

Which statement best describes the proposed mechanism of low-dose naltrexone?

A. It causes continuous opioid receptor blockade throughout the day.
B. It briefly and partially blocks opioid receptors, followed by compensatory upregulation of endogenous opioids.
C. It permanently increases opioid receptor density after one dose.
D. It works only by suppressing cortisol.

Correct answer: B.

Question 2

According to the sweet-spot model, what is the best interpretation when a highly sensitive patient feels worse shortly after starting LDN?

A. LDN always causes chronic endorphin depletion.
B. The patient should always be increased to 4.5 mg quickly.
C. The dose may be too high or the titration too fast for that patient.
D. LDN is contraindicated in all medication-sensitive patients.

Correct answer: C.

Question 3

Which symptom cluster is most consistent with the proposed endorphin deficiency phenotype?

A. Acute fever, rash, and hematuria.
B. Chronic pain, non-restorative sleep, fatigue, brain fog, and reduced stress tolerance.
C. Isolated hypertension with no fatigue.
D. Hyperthyroidism with tremor and weight loss.

Correct answer: B.

Question 4

Which patient group is most likely to require an ultra-low-dose or slow-titration LDN approach?

A. Patients with stable symptoms and no medication sensitivity.
B. Patients with medication sensitivity, ME/CFS, fibromyalgia, long COVID, or central sensitization.
C. Patients already tolerating high-dose naltrexone.
D. Patients using LDN only for short-term acute injury.

Correct answer: B.

References

Core references

1. Kim YH. Finding Your LDN Sweet Spot: A Simple Guide to Optimal Dosing. IFM Synergy. Published Jan 29, 2026.
2. Kim YH. Does Low-Dose Naltrexone Cause Endorphin Deficiency? Separating Mechanism from Myth in LDN Therapy. IFM Synergy. Published Feb 9, 2026.
3. Kim YH. The Endorphin Depletion Hypothesis in CFS/ME. IFM Synergy. Published Feb 23, 2026.
4. Kim YH. Low-Dose Naltrexone (LDN): A Functional Medicine Approach to Autoimmunity, Lyme Disease, Long COVID, and Chronic Pain. IFM Synergy. Published Apr 10, 2026.
5. Kim YH. LDN, Emotional Distress, Neuropathy, Chronic Fatigue Syndrome, and Mitochondrial Support. IFM Synergy. Published Mar 13, 2026.

Supporting references cited in your article set

1. Conti et al. Reported significantly decreased immunoreactive beta-endorphin in mononuclear leukocytes from CFS patients compared with healthy controls, as summarized in your CFS/ME article.
2. Panerai et al. Reported significantly lower PBMC beta-endorphin concentrations in CFS and fibromyalgia patients, as summarized in your CFS/ME article.
3. Effenberger M, et al. Does low-dose oral naltrexone alleviate symptoms of long COVID? A systematic review and meta-analysis. COVID. 2025;5(12):198, as cited in your functional medicine LDN review.
4. Cabanas H, et al. Low-dose naltrexone restored TRPM3 ion channel function in natural killer cells from long COVID patients. Frontiers in Molecular Biosciences. 2025;12:1582967, as cited in your functional medicine LDN review.